Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 6
Stacking GLP-1 Drugs With Mood Peptides
Tirzepatide and retatrutide users sometimes add peptides like Semax for energy or mood. Here is what the trial evidence actually supports.
AGA MetALD Update: Where GLP-1 Drugs Stand
The AGA's new practice update addresses MetALD, a liver disease combining metabolic risk and alcohol use, and what it says about semaglutide.
CJC-1295 With DAC vs Without DAC
CJC-1295 with DAC and without DAC are chemically different molecules with different half-lives, not two doses of the same peptide.
Photos vs Self-Report: GLP-1 Accuracy
A University of Michigan study compared medication photos against self-reports for 322 GLP-1 users and found real gaps in compounded-drug reporting.
Medicare's GLP-1 Bridge, By the Numbers
Eli Lilly says its drugs cover 70% of the 700,000 Medicare patients who started a GLP-1 since the temporary Bridge program opened in July 2026.
Novo Nordisk CEO open to NYSE upgrade
Novo Nordisk's CEO says a direct NYSE listing has advantages, a shift tied to Ozempic and Wegovy's US sales base and future R&D funding.
5mg vs 10mg Vials: What's Actually Missing
CJC-1295 and ipamorelin vial size doesn't decide potency. What's actually missing is any FDA-recognized reconstitution or stability standard for either peptide.
Semaglutide mechanism: the missing pieces
Semaglutide binds a well-mapped receptor, but a 2026 SELECT trial analysis shows weight loss explains only part of its heart benefit.
Semaglutide and Podocyte Senescence
Semaglutide cuts kidney disease events in trials. Researchers now ask whether slowing podocyte senescence in kidney filter cells explains part of why.
What explains semaglutide's heart benefit?
A SELECT trial mediation analysis finds weight, waist size and inflammation changes explain only a third of semaglutide's 20% cardiovascular risk reduction.
Semaglutide vs Older Diabetes Drugs
Semaglutide beats DPP-4 inhibitors like sitagliptin in trials, but head-to-head data against sulfonylureas and thiazolidinediones is thin.
Eating disorders in the GLP-1 era
GLP-1 drugs cut binge eating in trials and raise dietary restraint. Here is what clinicians are flagging on eating disorder risk, and what is unmeasured.